Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Francis Farraye MS, MSc

Francis A. Farraye MS, MSc

Professor of Medicine; Director, Inflammatory Bowel Disease Center, Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida

Francis A. Farraye, MD, MSc, is the director of the Inflammatory Bowel Disease Center at the Mayo Clinic, Jacksonville, Fla. and a professor of medicine at the Mayo Clinic School of Medicine and Science. A gastroenterologist and clinical investigator, he has been practicing medicine for 33 years. Dr. Farraye is a frequent speaker on IBD diagnosis and management and has authored or coauthored more than 450 scientific manuscripts, chapters, reviews and abstracts. He has served on innumerable national and international gastrointestinal committees. Dr. Farraye is editor in chief of Journal Scan published weekly by the American Society of Gastrointestinal Endoscopy. He coedited the publications Curbside Consultation in Inflammatory Bowel Disease and GI Emergencies.  The New England Crohn’s and Colitis Foundation named him their humanitarian of the year (2003) and gave him their lifetime achievement award (2020). In 2009, he received the William Carey Award from the American College of Gastroenterology for service to the college.


Dr. Farraye declares royalties or licenses from Jones and Bartlett, consulting fees from Arena, BMS, Braintree Labs, GI Reviewers, the GSK group of companies, IBD Educational Group, Innovation Pharmaceuticals, Iterative Scopes, Janssen, Pfizer, and Sebela, is a member of the data safety monitoring boards for Bacainn Therapeutics, Lilly and Theravance, and has stock or stock options in Innovation Pharmaceuticals.